30 results about "Antibiotic resistance" patented technology

The application discloses a Vibrio harveyi oral vaccine and a preparation method and application thereof. The application uses a lactococcus lactis NZ9000 expression system, modifies transformation parameters, effectively expresses Vibrio harveyi OmpU protein, constructs a lactococcus lactis (NZ9000) engineering bacterium expressing Vibrio harveyi outer membrane protein (OmpU), develops an oral vaccine against Vibrio harveyi infection, aims to reduce the infection of economic animals in seawater aquaculture by oral administration, provides a new scheme for dealing with the harm of Vibrio harveyi infection and antibiotic resistance and the like, promotes the breeding of fry and fingerlings, and promotes the development of biological agriculture and related industries. The strategy is expected to overcome the problems of traditional injection vaccines, such as inconvenient operation and great stress, and can provide a new technical scheme for reducing the dependence of the aquaculture industry on antibiotics and promoting the establishment of a green and healthy breeding mode.

This invention provides a method for monitoring and evaluating the risk of pathogenic bacteria transmission in poultry farm feces, belonging to the field of livestock and poultry biosecurity control technology. The method includes evaluating the risk of Salmonella transmission during the poultry physiological cycle, assessing the risk of antibiotic resistance associated with drug administration behavior, and monitoring the function during composting based on microbial community structure and metabolic function. This invention can accurately locate the highest-risk nodes of pathogen contamination and antibiotic resistance evolution during the breeding cycle, solving the problem of inaccurate identification of risk sources in existing technologies and avoiding poultry product contamination due to missed risk assessments. It overcomes the single-dimensional limitation of existing technologies that only detect the quantity of pathogens, comprehensively evaluating pathogen risk from phenotypic, molecular, and functional levels. The assessment results are more in line with the actual biosecurity needs of poultry farming, ultimately reducing the safety risks of poultry product contamination and the spread of antibiotic resistance.

This utility model belongs to the technical field of antibiotic-reduced feed production equipment, specifically disclosing a herbal medicine pulverizing device for antibiotic-reduced feed for livestock. It includes a fixed frame, a pulverizing mechanism, and a cooling mechanism, with the pulverizing mechanism fixedly connected to the fixed frame. The pulverizing mechanism includes a pulverizing cylinder and a grinding box arranged sequentially. The pulverizing cylinder has a feed inlet at the upper end and an arc-shaped filter screen at the lower end. A pulverizing roller is rotatably connected inside the pulverizing cylinder. The grinding box has a discharge outlet at the lower end and a grinding roller assembly is rotatably connected inside the grinding box. The cooling mechanism includes a water-cooling jacket, a water pump, a water supply pipe, and a return water pipe. This utility model, by adding a water-cooling jacket to the outside of the pulverizing mechanism and continuously supplying cold water to the water-cooling jacket via a water pump for heat exchange, promptly reduces the temperature in the working cavity of the pulverizing mechanism, preventing excessive temperature accumulation in the working cavity and thus avoiding the heat loss of heat-sensitive active ingredients in the herbal medicine.

This invention discloses a strain of *Bacillus saeformis* H1, its culture method, and its applications, relating to the field of microbial technology. The strain was deposited on March 31, 2026, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 38117. This strain exhibits strong environmental adaptability, can stably grow under neutral to strongly alkaline conditions, and secretes antibacterial substances with low toxicity and no pathogenicity. After optimization, its optimal liquid fermentation conditions are: 5 g / L yeast extract, 10 g / L peptone, 37 g / L sucrose, pH=10, temperature 25℃, rotation speed 140 rpm, and culture time 24 h. The fermentation supernatant of this strain shows significant inhibitory effects on Gram-positive bacteria such as *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus*, and *Streptococcus pneumoniae*, and can be prepared into drug sensitivity tablets. The *Bacillus saeformis* H1 provided by this invention can be used to prepare antibacterial drugs or antibacterial infection drugs, providing a new strategy for alleviating the problem of antibiotic resistance.

A process and system for removal of antibiotic compounds from a patient's body can include having a patient digest an antibiotic removal agent or an antibiotic deactivation agent. The agent can include anionic hairy cellulose nanocrystals (AHCNC) hybridized with a resin, such as cholestyramine (CHA). The agent can pass through the patient's digestive system to remove antibiotic compounds that may reside therein as a consequence of an antibacterial treatment provided to the patient. Removal of the antibiotic compounds from the patient's digestive system can avoid evolution of antimicrobial resistance.

The application discloses application of bio-organic acid in preparation of plasmid conjugation transfer inhibitor and / or antibacterial drugs. The bio-organic acid in the application includes one or more of citric acid, fumaric acid or alpha-ketoglutaric acid. The application finds the possibility of the bio-organic acid as the conjugation transfer inhibitor in preventing and controlling the spread of antibiotic resistance level through in-vivo and in-vitro conjugation tests. The application provides the use of the bio-organic acid as the conjugation transfer inhibitor, limits the conjugation transfer of various clinical drug-resistant plasmids, and is one of strategies for solving the problem of bacterial drug resistance.

DEPCT6604 / 07 / 2566 This invention involves a DNA structure suitable for expression. Recombinant proteins in bacterial host cells that include the following DNA structure: Coding nucleotide sequence: promoter rhaBAD, RhaR transcription activater, RhaS Transcription activators, antibiotic resistance indicators, actively linked promoters. Along with nucleic acids that encode indicators of antibiotic resistance, the terminators rrnBT1 and rrnBT2. The point for initiating self-replication, pMB1, is a DNA structure that may also be assembled with sequences. The nucleotides that encode the recombinant protein are functionally linked to the promoter. This invention, rhaBAD, involves, in addition to a vector and a bacterial host cell that are combined. Given this DNA structure and the method of producing recombinant proteins... By contacting the host bacterial cells with rhamnose, the expression of these cells is stimulated. Of the aforementioned recombinant proteins;

Provided herein are methods of targeted genomic sequencing requiring only a single amplification step. The Single Amplification Sequencing (SAS) assay provided herein amplies and sequences targeted genomic regions at reduced time and cost. The assay provides robust coverage and accurate drug resistance profiles for multiple first- and second-line Tuberculosis drugs, showcasing its clinical utility for rapid antimicrobial resistance (AMR) detection. SAS significantly simplifies targeted Next Generation Sequencing (tNGS) workflows and holds significant promise for revolutionizing precision diagnostics across a wide array of clinical and research settings.

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-like receptor 7 (TLR7) agonistfor use as a medicament or for use in the treatment of cancer, an antibiotic resistance, an inflammatory condition or disease, an autoimmune disease or an infectious disease and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition and a kit or kit of parts comprising the pharmaceutical composition for use.

This invention discloses an antibiotic patch and its application. The antibiotic patch includes a transdermal microneedle module, an antibiotic reservoir layer, and an osmotic pressure driving module, with the reservoir layer and the driving module separated by an elastic membrane. The osmotic pressure driving module includes a water chamber, a propulsion layer, and an osmotic pressure active sheet. It generates a constant thrust through unidirectional permeation of the semi-permeable membrane, propelling the antibiotic through the hollow microneedles for transdermal infusion and achieving zero-level release. The independent antibiotic reservoir layer can hold large doses of antibiotics, and it is also equipped with a filling port and a venting port to ensure flexible and stable medication administration. The antibiotic patch is suitable for various scenarios, including home and outdoor use, and can reduce the risk of antibiotic resistance and side effects, providing a convenient and efficient new solution for the treatment of bacterial infections.

This invention discloses an antimicrobial peptide RY-10 and its application in the preparation of antimicrobial drugs, belonging to the field of biomedical technology. The amino acid sequence of the antimicrobial peptide RY-10 is shown in SEQ ID NO.2. The antimicrobial peptide RY-10 provided by this invention has a highly efficient killing ability against a variety of Gram-negative / positive bacteria, effectively retaining antimicrobial activity while significantly reducing cytotoxicity. Simultaneously, this antimicrobial peptide RY-10 can also produce synergistic antimicrobial effects with various antibiotics, showing significant application value in improving efficacy, overcoming antibiotic resistance, reducing drug dosage, delaying the development of drug resistance, and addressing complex infections. This invention provides a highly promising candidate material resource for the development of highly effective and low-toxicity antimicrobial drugs, and also provides an efficient, safe, and sustainable solution for developing novel combination therapies and addressing the global drug resistance crisis, possessing significant clinical application value and industrialization potential.

Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided for treating biofilms without inducing antimicrobial resistance.

The application provides application of paracasei or a postbiotic thereof in preparation of a product for regulating sebum metabolism, and relates to the technical field of microbial postbiotics. Lacticaseibacillus paracasei CCFM1224 or the postbiotic thereof has an improvement effect on sebum metabolism disorder, and the molecular mechanism of regulating sebum metabolism is clear, so that a new functional component is provided for a product for regulating sebum metabolism. The application provides a theoretical basis for application of the postbiotic in regulation of sebum metabolism disorder, provides a new functional component for a sebum metabolism related disease or a cosmetic product, has high safety and good stability, solves the problems of antibiotic resistance, hepatotoxicity, teratogenicity and other adverse reactions, avoids limitation of strain activity and colonization ability, and has a good application prospect.

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-like receptor 7 (TLR7) agonist for use as a medicament or for use in the treatment of cancer, an antibiotic resistance, an inflammatory condition or disease, an autoimmune disease or an infectious disease and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition and a kit or kit of parts comprising the pharmaceutical composition for use.

Disclosed herein is an oral fish vaccine comprising a recombinant cell comprising virus-like particles, wherein the recombinant cell is intact, inactivated, and does not exhibit antibiotic resistance. In one preferred embodiment, the inactivation is performed using sodium hypochlorite. In another preferred embodiment, the recombinant cell is Escherichia coli (E. coli) or Lactococcus lactis (L lactis). In a further preferred embodiment, the virus-like particles comprise nervous necrosis virus capsid proteins and the vaccine is used in treating or preventing viral nervous necrosis.

The present application belongs to the technical field of traditional Chinese medicine, and specifically relates to a Dai Baijie-Yangtao composition, a preparation method thereof and application of the Dai Baijie-Yangtao composition in the treatment of ulcerative colitis. The Dai Baijie-Yangtao composition is prepared by mixing a Dai Baijie water extract and a Yangtao water extract at a ratio of 1:1. The composition can be administered orally and can effectively treat ulcerative colitis, has the effects of anti-inflammation, relieving intestinal bleeding, recovering colon length, regulating intestinal flora structure (increasing the number of beneficial bacteria), and also has a liver protection effect on non-alcoholic hepatitis. The preparation method is simple, the instruments are general, and the method is easy to industrialize. Based on the theory of ethnic medicine, the method has no risk of antibiotic resistance, is suitable for the needs of green breeding and clinical medication, and has high clinical application potential.

The present application provides a kind of palmatine derivative, the structural general formula is as follows: the present application selects palmatine as raw material, through multi-step synthesis, corresponding compound with high yield can be obtained, the palmatine derivative can effectively resist antibiotic resistant helicobacter pylori strain, especially spherical mutant strain, has good bacteriostatic activity, solves the antibiotic resistance and retention recurrence problem of helicobacter pylori in clinical treatment, is suitable for industrial production and clinical application.

This invention belongs to the field of biomedical technology and discloses an α-hemolysin inhibitor and its application in the preparation of anti-infective drugs for Staphylococcus aureus. The inhibitor is mangiferin, and its novel use as a small molecule inhibitor of Staphylococcus aureus α-hemolysin (Hla) and related drug preparation methods are described. This invention, through in vitro hemolysis experiments, Hla protein purification and inhibitory activity verification, binding stability experiments, molecular docking studies, and in vivo animal experiments, confirms that mangiferin can efficiently and directly inhibit the hemolytic activity of Staphylococcus aureus supernatant and purified Hla protein in a dose-dependent manner; it can form a stable complex with Hla protein through hydrogen bonds and other interactions, blocking the pore-breaking activity of Hla in an irreversible or high-affinity binding manner, with a long-lasting inhibitory effect. This invention provides a novel candidate drug and technical solution for solving the problems of Staphylococcus aureus (including drug-resistant strains) infection and antibiotic resistance, with broad application prospects.

This invention belongs to the field of microbial technology, specifically relating to a highly efficient Arthrobacterium X-6 that degrades sulfonamide antibiotics and its applications. The highly efficient Arthrobacterium X-6 that degrades sulfonamide antibiotics provided by this invention (… Paenarthrobacter sp. Arthroblast X-6, deposited on January 19, 2026, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 37463, provides this invention. Arthroblast X-6 can grow using seven common antibiotic resistance (SA) species as its sole carbon source, exhibiting a highly efficient degradation capacity for SA species, reaching up to 100%. It not only possesses environmental remediation potential but also minimizes the risk of secondary pollution. Furthermore, it is inexpensive and environmentally friendly, achieving highly efficient microbial control of antibiotic-resistant environmental transmission and providing strain resources and theoretical data for the remediation of SA species contamination.

This invention relates to an integrative plasmid for multicopy iteration of the Saccharomyces cerevisiae genome and its application, belonging to the field of biotechnology. This invention first constructs a multicopy integration vector, using Ty1, Ty2, Ty3, and Ty4 as multicopy integration target sites to construct four integrative plasmids. Each plasmid carries a fluorescent protein reporter gene (mScarlet-I or GFP) and an antibiotic resistance marker gene (such as hygromycin or genistein) to enable visualization and screening of the integration site. Applied to the preparation of nervonic acid, it achieves continuous editing without the need for monoclonal isolation. The strain obtained in the fourth round was screened by plate fermentation and verified in a 3 L fermenter, yielding a high nervonic acid production strain.

The application relates to the field of biomedical technology, and discloses a smart hydrogel based on copper sulfide nanomaterial, a preparation method and application. By constructing a hydrogel system for treating diabetic wounds with the effects of blood sugar control, antibiosis and wound healing promotion, on one hand, glucose oxidase is used to catalytically decompose glucose on a wound surface to reduce the blood sugar concentration; on the other hand, the oxidative dynamics and the photothermal conversion performance of copper sulfide nanomaterial are used to inhibit infection in a dual antibacterial activity mode to avoid the risk of antibiotic resistance; the hydrogel is used as a carrier to realize controllable release of the two, and meanwhile, the hydrogel can maintain the moisture of the wound surface and synergistically promote cell proliferation and blood vessel regeneration. The smart hydrogel based on copper sulfide nanomaterial prepared by the application breaks through the limitation of the existing single-function product, and as a drug for treating diabetic wounds, the healing efficiency of the wound is improved, and the two core problems of the high blood sugar microenvironment and the susceptibility to multiple drug-resistant bacterial infection in the healing of diabetic wounds are solved.

To address the growing challenge of antibiotic resistance globally, this invention develops a Fmoc-tyrosine / berberine chiral supramolecular antibacterial hydrogel with photodynamic therapy. This is achieved by exploring the synergistic effect of berberine (BBR) in supramolecular chiral assembly. Berberine, the main active ingredient in the traditional Chinese medicine (TCM) Coptis chinensis, co-assembles with Fmoc-tyrosine (Fmoc-Y) to form a chiral supramolecular antibacterial hydrogel, effectively utilizing the chirality of amino acids and the antibacterial potential of BBR. Studies have confirmed that supramolecular assembly possesses photodynamic therapy (PDT) capabilities. Under white light, the chiral supramolecular assemblies can effectively generate type I and type II free radicals, enhancing their antibacterial activity against common bacteria such as Escherichia coli and Staphylococcus aureus. Furthermore, the chiral hydrogel exhibits good biocompatibility, low cytotoxicity, and hemolytic activity, indicating its potential application in the field of safe biomedicine. This invention demonstrates the therapeutic potential of combining TCM compounds with supramolecular chiral assembly, opening up a new treatment approach for bacterial infections and addressing antibiotic resistance.

The present application relates to a strain of Bacteroides fragilis and its application, the strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 14, 2026, and the preservation number is: CGMCC No. 38257.The strain can regulate STING-dependent training immunity, effectively resist Salmonella typhimurium and H9N2 avian influenza virus infection, maintain the integrity of the intestinal barrier of the host, and reduce inflammatory damage.The Bacteroides fragilis of the present application has good biological safety, and the strain can be used as a training immunity inducer, and the strain is expected to be a candidate probiotic or vaccine adjuvant for preventing / treating bacterial and viral infections, suitable for human health and poultry farming, and provides a new solution to resist antibiotic resistance.

The application discloses an antibacterial peptide RK-8 and application thereof in preparation of antibacterial drugs, and belongs to the technical field of biological medicine. The amino acid sequence of the antibacterial peptide RK-8 is shown as SEQ ID NO. 2. The antibacterial peptide RK-8 provided by the application has high killing capacity on various gram-negative / positive bacteria, effectively retains antibacterial activity, greatly reduces cytotoxicity, and improves treatment effect. Meanwhile, the antibacterial peptide RK-8 can also produce synergistic antibacterial effect with various antibiotics, has significant application value in improving curative effect, overcoming antibiotic resistance, reducing drug dosage, delaying drug resistance, and coping with complex infections. The application provides a promising candidate substance resource for developing high-efficiency and low-toxicity antibacterial drugs, and provides an efficient, safe and sustainable solution for developing a new combined therapy and coping with the global drug resistance crisis, and has important clinical application value and industrialization potential.

This invention proposes a compound plant composition for inhibiting intestinal inflammatory response in pigs, its preparation method, and its application, relating to the field of veterinary technology. The compound plant composition contains the following active ingredients in parts by weight: 50-70 parts carvacrol, 10-20 parts thymol, 30-50 parts cinnamaldehyde, 5-10 parts baicalein, 5-10 parts apigenin, and 3-8 parts chlorogenic acid. The preparation method involves mixing the active ingredients in proportion, adding water and Tween-80, and stirring until homogeneous. This invention can significantly reduce the levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in the serum and small intestinal tissue of pigs infected with enterotoxigenic Escherichia coli, and increase the level of the anti-inflammatory cytokine IL-10. It also exerts its anti-inflammatory effect by inhibiting the activation of the TLR4-MyD88-NF-κB signaling pathway. This invention uses a compound of natural plant extracts, eliminating the risk of antibiotic resistance and veterinary drug residues, and is simple to prepare.

This invention relates to the field of biopharmaceutical technology, specifically to a BTO / PB acoustic pressure electrocatalytic nanoplatform ointment, its preparation method, and its application. The ointment is an injectable BTO / PB acoustic pressure electrocatalytic nanoplatform ointment formed by combining a barium titanate and Prussian blue composite nanomaterial with an ointment. The BTO / PB acoustic pressure electrocatalytic nanoplatform ointment of this invention exhibits excellent biocompatibility. Unlike traditional antibiotics, BTO / PB generates ROS (reactive oxygen species) through an ultrasound-driven catalytic reaction, independent of antibiotics, thus eliminating the risk of drug resistance. It effectively addresses the increasingly serious problem of antibiotic resistance, has a good antibacterial effect against periodontal pathogens, significantly alleviates gingival inflammation, reduces the infiltration of inflammatory cells, lowers the expression of inflammatory factors, and effectively inhibits osteoclast activity, thereby protecting alveolar bone and maintaining the integrity of periodontal tissues.

The present invention relates to a method for preparing a bactericidal phage vector, (pharmaceutical) compositions comprising such phage vectors, also for use in treating diseases, particularly those caused by (antimicrobial resistance) bacterial cells.

A bacterial antimicrobial resistance prediction method and system, a hierarchical configuration unit divides resistance prediction elements into patient risk levels, microbial feature levels, regional prevalence levels, clinical rule levels and drug property levels, each level includes initial attribute values and level-specific dynamic rule sets; a data processing unit acquires real-time clinical data, each level independently processes data through its level-specific dynamic rule set, and converts initial attribute values into target attribute values; a decision superposition unit superimposes the target attribute values of each level according to the weight priority of each level to generate a bacterial antimicrobial resistance prediction result and an antibacterial drug recommendation scheme; a report output unit outputs a visual report. The present application realizes precise, interpretable and highly adaptive bacterial antimicrobial resistance prediction through hierarchical design and rule monitoring separation architecture, while reducing the dependence on high-performance equipment and adapting to the use scenarios of primary medical institutions.

This invention provides a recombinant plasmid for expressing the Bacillus subtilis resistance marker gene without antibiotic resistance, its construction method, and its application. This invention utilizes Bacillus subtilis SCK6 supercompetent cells to directly construct a Bsggt recombinant expression plasmid that does not contain the Ori replication origin site of Escherichia coli or the ampicillin resistance gene. This results in a smaller free plasmid expression system, providing a stable expression tool for heterologous proteins in production applications. The use of Cas9n-AID base editing technology in this invention simplifies the strain screening process. The constructed resistance marker-free expression plasmid is smaller than traditional shuttle plasmids, and no inducing agent is needed during expression. Because the expression plasmid is free of antibiotic resistance markers, the growth rate is significantly increased during culture due to the absence of antibiotic pressure. High expression without antibiotic introduction is more suitable for food safety-grade production applications.